Andreas Bockisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andreas Bockisch has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Gerald Antoch
Institut für Diagnostische und Interventionelle Radiologie, Heinrich-Heine-Universität Düsseldorf
5 shared publications - Gerald Antoch
Universitätsklinikum Düsseldorf, Institut für Diagnostische und Interventionelle Radiologie, Düsseldorf
5 shared publications - Lutz Stefan Freudenberg
Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
5 shared publications - Walter Jentzen
Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, Germany
4 shared publications - Hilmar Kuehl
Universitätsklinikum Essen
3 shared publications Jörg F Debatin
3 shared publications
Latest Publications
- 1 September 2017
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 56 (05) , 162-170
Selektive intraarterielle Radiotherapie (SIRT) maligner Lebertumoren
These guidelines aim to support medical personnel and physicians working in oncology in selecting appropriate patients, in treatment planning, preparation and implementation of SIRT for the treatment of primary and secondary liver malignancies. The focus lies on the requirements in the treatment center with regard to staffing, technical, and organizational aspects including radiation safety. Patient selection need to be performed in an interdisciplinary tumor board including the medical team tasked with the treatment and a medical physics expert. The aims of the treatment, the workup necessary for patient selection and treatment planning, and for avoiding complications are presented as are the requirements for obtaining informed consent from the patient. The follow-up of patients after SIRT also requires interdisciplinary cooperation, including communication with the local family physician. Die Leitlinie soll medizinisches Fachpersonal und onkologisch tätige Ärzte bei der Auswahl geeigneter Patienten, der Planung, Vorbereitung und Durchführung einer SIRT zur Behandlung primärer und sekundärer maligner Lebertumoren unterstützen. Schwerpunkte sind personelle, technische und organisatorische Anforderungen an das Therapiezentrum einschließlich Strahlenschutz, d. h. insbesondere die Notwendigkeit einer interdisziplinären Patientenselektion in Tumorboards und die Anforderungen an das Team, das die Therapie durchführt und einen Medizinphysikexperten einbeziehen muss. Die Zielsetzung der Therapie, die erforderlichen Daten und Voruntersuchungen für die Indikationsstellung und Therapieplanung und ihre Implikationen für die Vermeidung von Komplikationen werden dargestellt, ebenso Anforderungen an die Aufklärung des Patienten. Die Nachsorge wird beschrieben und auf die Notwendigkeit einer interdisziplinären Zusammenarbeit auch mit heimatnahen behandelnden Ärzten hingewiesen. * Stand: 12/2014 – AWMF-Registernummer: 031-048 * Herausgeber: Deutsche Gesellschaft für Nuklear medizin, Nikolaistraße 29, 37073 Göttingen, [email protected] * Weitere Beteiligte: European Association of Nuclear Medicine (EANM)
- 1 September 2017
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 56 (05) , 162-170
Selektive intraarterielle Radiotherapie (SIRT) maligner Lebertumoren
These guidelines aim to support medical personnel and physicians working in oncology in selecting appropriate patients, in treatment planning, preparation and implementation of SIRT for the treatment of primary and secondary liver malignancies. The focus lies on the requirements in the treatment center with regard to staffing, technical, and organizational aspects including radiation safety. Patient selection need to be performed in an interdisciplinary tumor board including the medical team tasked with the treatment and a medical physics expert. The aims of the treatment, the workup necessary for patient selection and treatment planning, and for avoiding complications are presented as are the requirements for obtaining informed consent from the patient. The follow-up of patients after SIRT also requires interdisciplinary cooperation, including communication with the local family physician. Die Leitlinie soll medizinisches Fachpersonal und onkologisch tätige Ärzte bei der Auswahl geeigneter Patienten, der Planung, Vorbereitung und Durchführung einer SIRT zur Behandlung primärer und sekundärer maligner Lebertumoren unterstützen. Schwerpunkte sind personelle, technische und organisatorische Anforderungen an das Therapiezentrum einschließlich Strahlenschutz, d. h. insbesondere die Notwendigkeit einer interdisziplinären Patientenselektion in Tumorboards und die Anforderungen an das Team, das die Therapie durchführt und einen Medizinphysikexperten einbeziehen muss. Die Zielsetzung der Therapie, die erforderlichen Daten und Voruntersuchungen für die Indikationsstellung und Therapieplanung und ihre Implikationen für die Vermeidung von Komplikationen werden dargestellt, ebenso Anforderungen an die Aufklärung des Patienten. Die Nachsorge wird beschrieben und auf die Notwendigkeit einer interdisziplinären Zusammenarbeit auch mit heimatnahen behandelnden Ärzten hingewiesen. * Stand: 12/2014 – AWMF-Registernummer: 031-048 * Herausgeber: Deutsche Gesellschaft für Nuklear medizin, Nikolaistraße 29, 37073 Göttingen, [email protected] * Weitere Beteiligte: European Association of Nuclear Medicine (EANM)
- Open Access
- 1 November 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (11) , 3833-3834
Malignant Pheochromocytoma Imaging with [124I]mIBG PET/MR
Pheochromocytoma localized in the adrenal medulla (in 85%) or in the thoracic/abdominal sympathetic trunk (paraganglioma) has malignant potential in about 10% of cases. Metaiodobenzylguanidine (mIBG) can be labeled with 123-iodine (for scintigraphy), 131-iodine (basically for therapy), or 124-iodine [excellent positron emission tomography (PET) imaging and tumor dosimetry based on high spatial resolution] and has high sensitivity for the diagnosis of primary/metastatic pheochromocytoma (1–3).
- 1 November 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (11) , 3833-3834
Open AccessMalignant Pheochromocytoma Imaging with [124I]mIBG PET/MR
Pheochromocytoma localized in the adrenal medulla (in 85%) or in the thoracic/abdominal sympathetic trunk (paraganglioma) has malignant potential in about 10% of cases. Metaiodobenzylguanidine (mIBG) can be labeled with 123-iodine (for scintigraphy), 131-iodine (basically for therapy), or 124-iodine [excellent positron emission tomography (PET) imaging and tumor dosimetry based on high spatial resolution] and has high sensitivity for the diagnosis of primary/metastatic pheochromocytoma (1–3).
- 1 June 2011
- Published by The Endocrine Society
- p. P2-634
Peptide Receptor Radionuclide Therapy of a Patient with Metastatic Cervical Paraganglioma Due to a Novel SDHD Gene Mutation (H102R)
Article published by the Endocrine Society Article published by the Endocrine Society
- 1 June 2011
- Published by The Endocrine Society
- p. P2-634
Peptide Receptor Radionuclide Therapy of a Patient with Metastatic Cervical Paraganglioma Due to a Novel SDHD Gene Mutation (H102R)
Article published by the Endocrine Society Article published by the Endocrine Society
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , -805-805
745 The Role of Selective Internal Radiotherapy with Yttrium-90 Glass Microspheres in Advanced Hepatocellular Carcinoma +/− Portal Vein Thrombosis – A European Pilot Phase II Study
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , -805-805
745 The Role of Selective Internal Radiotherapy with Yttrium-90 Glass Microspheres in Advanced Hepatocellular Carcinoma +/− Portal Vein Thrombosis – A European Pilot Phase II Study
- 31 August 2007
- Published by Elsevier in Academic Radiology
- Vol. 14 (8) , 967-973
Economic Image Compression of Output Documentation of the Most Frequent Examinations in Nuclear Medicine
- 31 August 2007
- Published by Elsevier in Academic Radiology
- Vol. 14 (8) , 967-973
Economic Image Compression of Output Documentation of the Most Frequent Examinations in Nuclear Medicine
- 1 January 2007
- Vol. 48 (1) , 108-14
Segmentation of PET volumes by iterative image thresholding.
The segmentation of metastatic volumes in PET is usually performed by thresholding methods. In a clinical application, the optimum threshold obtained from the adaptive thresholding method requires a priori estimation of the lesion volume from anatomic images such as CT. We describe an iterative thresholding method (ITM) used to estimate the PET volumes without anatomic a priori knowledge and its application to clinical images. The ITM is based on threshold-volume curves at varying source-to-background (S/B) ratio acquired from a body phantom. The spheres and background were filled either with (18)F-FDG or Na(124)I ((124)I). These calibrated S/B-threshold-volume curves were used in estimating the volume by applying an iterative procedure. The ITM was validated with a PET phantom containing spheres and with 39 PET tumors that were discernable on CT by using whole-body (18)F-FDG (15 patients) and (124)I PET/CT (9 patients): The measured S/B ratios of the lesions were estimated from PET images, and their volumes were iteratively calculated using the calibrated S/B-threshold-volume curves. The resulting PET volumes were then compared with the known sphere inner volume and CT volumes of tumors that served as gold standards. Phantom data analysis showed that the S/B-threshold-volume curves of (18)F-FDG and (124)I were similar. The average absolute deviation (expressed as a percentage of the expected volume) obtained in the PET validation phantom was 10% for volumes larger than 1.0 mL; sphere volumes of 0.5 mL showed a significantly larger deviation. For patients, the average absolute deviation for volumes between 0.8 and 7.5 mL was about 9% (31 lesions), whereas volumes larger than 7.5 mL showed an average volume mismatch of 15% (8 lesions). The ITM sufficiently estimated the clinical volumes in the range of 0.8-7.5 mL; volumes larger than 7.5 mL showed greater deviations that were still acceptable. These findings are associated with the limitation of the ITM. The ITM is especially useful for lesions that are only visible on PET. As a consequence, the lesion dosimetry is feasible with sufficient accuracy using PET images only.
- 1 January 2007
- Vol. 48 (1) , 108-14
Segmentation of PET volumes by iterative image thresholding.
The segmentation of metastatic volumes in PET is usually performed by thresholding methods. In a clinical application, the optimum threshold obtained from the adaptive thresholding method requires a priori estimation of the lesion volume from anatomic images such as CT. We describe an iterative thresholding method (ITM) used to estimate the PET volumes without anatomic a priori knowledge and its application to clinical images. The ITM is based on threshold-volume curves at varying source-to-background (S/B) ratio acquired from a body phantom. The spheres and background were filled either with (18)F-FDG or Na(124)I ((124)I). These calibrated S/B-threshold-volume curves were used in estimating the volume by applying an iterative procedure. The ITM was validated with a PET phantom containing spheres and with 39 PET tumors that were discernable on CT by using whole-body (18)F-FDG (15 patients) and (124)I PET/CT (9 patients): The measured S/B ratios of the lesions were estimated from PET images, and their volumes were iteratively calculated using the calibrated S/B-threshold-volume curves. The resulting PET volumes were then compared with the known sphere inner volume and CT volumes of tumors that served as gold standards. Phantom data analysis showed that the S/B-threshold-volume curves of (18)F-FDG and (124)I were similar. The average absolute deviation (expressed as a percentage of the expected volume) obtained in the PET validation phantom was 10% for volumes larger than 1.0 mL; sphere volumes of 0.5 mL showed a significantly larger deviation. For patients, the average absolute deviation for volumes between 0.8 and 7.5 mL was about 9% (31 lesions), whereas volumes larger than 7.5 mL showed an average volume mismatch of 15% (8 lesions). The ITM sufficiently estimated the clinical volumes in the range of 0.8-7.5 mL; volumes larger than 7.5 mL showed greater deviations that were still acceptable. These findings are associated with the limitation of the ITM. The ITM is especially useful for lesions that are only visible on PET. As a consequence, the lesion dosimetry is feasible with sufficient accuracy using PET images only.
- 1 January 2007
- p. 45S-57S
Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen.
Stage-adapted treatment in oncology relies on correct tumor staging for patients with malignant diseases. To ensure accurate assessment of the tumor stage in thoracic and abdominal diseases by PET/CT, both CT and PET need to be optimized. In this setting, different malignant diseases require customized imaging protocols. Although in the clinical setting of therapy assessment, PET/CT with integration of low-dose, nonenhanced CT may be sufficient, tumor staging may require a more sophisticated CT protocol. This review focuses on potential CT protocols for imaging cancers of the chest and abdomen. Examples of CT protocols are presented and discussed for non-small cell lung cancer, breast cancer, colorectal cancer, gastrointestinal stromal tumors, and interventional liver therapy.
- 1 January 2007
- p. 45S-57S
Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen.
Stage-adapted treatment in oncology relies on correct tumor staging for patients with malignant diseases. To ensure accurate assessment of the tumor stage in thoracic and abdominal diseases by PET/CT, both CT and PET need to be optimized. In this setting, different malignant diseases require customized imaging protocols. Although in the clinical setting of therapy assessment, PET/CT with integration of low-dose, nonenhanced CT may be sufficient, tumor staging may require a more sophisticated CT protocol. This review focuses on potential CT protocols for imaging cancers of the chest and abdomen. Examples of CT protocols are presented and discussed for non-small cell lung cancer, breast cancer, colorectal cancer, gastrointestinal stromal tumors, and interventional liver therapy.
- 15 August 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (11) , 1247-1248
124I in PET imaging: impact on quantification, radiopharmaceutical development and distribution
- 15 August 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (11) , 1247-1248
124I in PET imaging: impact on quantification, radiopharmaceutical development and distribution
- 1 November 2004
- Published by Springer Nature in Der Radiologe
- Vol. 44 (11) , 1045-1054
Grundlagen und klinischer Nutzen von PET-CT
- 1 November 2004
- Published by Springer Nature in Der Radiologe
- Vol. 44 (11) , 1045-1054
Grundlagen und klinischer Nutzen von PET-CT
- 1 August 2004
- Published by Elsevier in Molecular Imaging and Biology
- Vol. 6 (4) , 188-199
Positron emission tomography/computed tomography?imaging protocols, artifacts, and pitfalls
- 1 August 2004
- Published by Elsevier in Molecular Imaging and Biology
- Vol. 6 (4) , 188-199
Positron emission tomography/computed tomography?imaging protocols, artifacts, and pitfalls